MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation

Table 1 Clinicopathological characteristics of patients with gastric cancer

Clinicopathological characteristics	No. of patients	miR-320a low expression	miR-320a high expression	χ2	P value
Age (yr)
≤ 60	25	15	10	0.285	0.594
> 60	59	39	20
Gender
Female	20	11	9	0.986	0.321
Male	64	43	21
Location
Gastric body	20	15	5	1.524	0.467
Gastric antrum	52	31	21
Gastric fundus	12	8	4
Tumor size (cm)
< 5	25	15	10	0.285	0.594
≥ 5	59	39	20
Differentiation
Poor	55	40	15	4.945	0.026
Well and moderate	29	14	15
TNM stage
I+II	34	15	19	10.120	0.001
III+ IV	50	39	11
Lymph node metastasis
No	18	7	11	6.436	0.011
Yes	66	47	19

Table 2 Primer/mimic sequences

Name	Sequence (5’–3’)
miR-320a reverse transcription primer
miR-320a	GTCTGTATGGTTGTTCTCGACTCCTTCACATCCCTATCCAACCATACAGACTCGCCCTC
U6 snRNA	GGAACGCTTCACGAATTTG
Real-time PCR primer sequence
miR-320a	FO:AAGGGATCGCGGGCG
	RE:TGCGTGTCGTGGAGTC
U6 snRNA	FO:ATTGGAACGATACAGAGAAGATT
	RE:GGAACGCTTCACGAATTTG
MSP primer sequence
Methylated	FO:ACGTCGTAATGTGAGGATTC
	RE:CGCAAACAAAACTCGATATAA
Nonmethylated	FO:ATTATGTTGTAATGTGAGGATTT
	RE:CACAAACAAAACTCAATATAACCC
miR-320a mimics sequence
miR-320a	Sense: AAAAGCUGGGUUGAGAGGGCGA
	Antisense: GCCCUCUCAACCCAGCUUUUUU
Negative control	Sense: UUCUUCGAACGUGUCACGUTT
	Antisense: ACGUGACACGUUCGGAGAATT
PBX3 primer sequence	FO:GCCAAATTGACCCAGATCAGAC
	RE:GAAATGGGACGTGTTCTACTCTGTT

PCR: Polymerase chain reaction.